News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Radius Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting


10/15/2012 9:15:02 AM

CAMBRIDGE, MA--(Marketwire - October 12, 2012) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, will present scientific data from studies conducted with BA058 at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting, in Minneapolis, Minnesota, October 12-15, 2012.

The data will be presented in three posters and one oral presentation:

BA058, a Novel Human PTHrP Analog, Restores Bone Density at the Spine and Femur in Osteopenic Sprague-Dawley Rats within 13 Weeks
Poster: October 13, 11.00 am - 1:00 pm, Discovery Hall B, Minneapolis Convention Center

BA058, a Novel Human PTHrP Analog, Restores Bone Mass in the Aged Osteopenic Ovariectomized Cynomolgus Monkey
Poster: October 15, 11.30 am - 1:30 pm, Discovery Hall B, Minneapolis Convention Center

Rapid Transdermal Delivery of BA058 by sMTS Microneedle Arrays: Pharmacokinetics in Rats and Monkeys, and Reversal of Bone Loss in Osteopenic Rats
Poster: October 15, 11.30 am - 1:30 pm, Discovery Hall B, Minneapolis Convention Center

Transdermal Delivery of BA058, A Novel Analog of hPTHrP, with a Short Wear Time Microneedle Skin Patch in Post-Menopausal Women
Oral Presentation: October 15, 3:30 pm - 3:45 pm, Room 101C, Minneapolis Convention Center

About BA058

BA058-Subcutaneous (BA058-SC) is a novel, synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein) that the Company is developing as an anabolic (bone-building) drug for the treatment of osteoporosis. There is increasing evidence that hPTHrP is critical in the formation of the embryonic skeleton and in the regulation of bone formation, with a distinct role from PTH (which primarily regulates calcium homeostasis and bone resorption), and is able to rebuild bone with low associated risk of inducing hypercalcemia as a side effect. BA058 is currently undergoing Phase 3 evaluation for the treatment of postmenopausal osteoporosis.

In a Phase 2 clinical trial, BA058-SC produced faster and greater bone mineral density (BMD) at the spine and hip after six months and 12 months of therapy, with greater BMD gains relative to Forteo®, the reference drug used in the study.

BA058-Transdermal (BA058-TD) is a short wear-time transdermal patch based on 3M's patented Microstructured Transdermal System technology to administer BA058 through the skin using a patch technology platform. The once-daily application of BA058-TD is expected to build new bone rapidly and reduce risk of future fractures, with minimized risk of hypercalcemia. BA058-TD is also intended to provide a more convenient treatment alternative to injection that may also improve treatment compliance among osteoporosis patients with convenience and ease of use.

About Radius

Radius is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions. Radius is committed to the development of advanced therapeutics for the large and underserved osteoporosis market. The Company's lead product candidate, BA058-SC, is in development to reduce the risk of complications associated with osteoporosis, such as fracture. The Company also has a next-generation transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause.

Safe Harbor for Forward-Looking Statements

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the development of Radius' products, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Radius or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Radius to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of Radius' proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that Radius may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius' business, financial conditions and results of operations are contained in Radius' filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The forward-looking statements represent Radius' estimate as of the date hereof only, and Radius specifically disclaims any duty or obligation to update forward-looking statements


CONTACT:

Radius Health
Corporate
Nick Harvey
CFO
617-551-4700

LaVoie Group
Media & Investors
Amanda Murphy
978.745.4200 ext. 107
amurphy@lavoiegroup.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES